Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

• Главные авторы: Beate Schmoele-Thoma (Автор), Martin van Cleeff (Автор), Richard N. Greenberg (Автор), Alejandra Gurtman (Автор), Thomas R. Jones (Автор), Vani Sundaraiyer (Автор), William C. Gruber (Автор), Daniel A. Scott (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...